Evidence map›Paper›PMID 38979385›Full record

ArticlebioRxiv : the preprint server for biology2024

Zebrafish use conserved CLR and TLR signaling pathways to respond to fungal PAMPs in zymosan.

Erin Glass, Stephan L Robinson, Emily E Rosowski

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Erin GlassDepartment of Biological Sciences, Clemson University, Clemson, SC.
Stephan L RobinsonEukaryotic Pathogens Innovation Center, Clemson University, Clemson, SC.
Emily E RosowskiDepartment of Biological Sciences, Clemson University, Clemson, SC.ORCID 0000-0002-6761-1098

Funding

Deciphering macrophage versus neutrophil signaling and effector functions in immune responses in vivoR35GM147464 · NIGMS · CLEMSON UNIVERSITY · PI Emily Rosowski · 2022 to 2026
$1.8M
Developing an in vivo toolbox to interrogate the intracellular trafficking and killing of Aspergillus sporesR21AI164363 · NIAID · CLEMSON UNIVERSITY · PI ROSOWSKI, EMILY · 2022 to 2023
$411k
MENTOR: Medical Enrichment Through Opportunities in ResearchT35AI134643 · NIAID · CLEMSON UNIVERSITY · PI SMITH, KERRY SCOT · 2018 to 2023
$118k
NIAID NIH HHS R21 AI164363NIAID NIH HHS T35 AI134643NIGMS NIH HHS R35 GM147464
6 · The paper itself

Abstract

Pattern recognition receptors (PRRs) such as C-type lectin receptors (CLRs) and Toll-like receptors (TLRs) are used by hosts to recognize pathogen-associated molecular patterns (PAMPs) in microorganisms and to initiate innate immune responses. While PRRs exist across invertebrate and vertebrate species, the functional homology of many of these receptors is still unclear. In this study, we investigate the innate immune response of zebrafish larvae to zymosan, a β-glucan-containing particle derived from fungal cell walls. Macrophages and neutrophils robustly respond to zymosan and are required for zymosan-induced activation of the NF-κB transcription factor. Full activation of NF-κB in response to zymosan depends on Card9/Syk and Myd88, conserved CLR and TLR adaptor proteins, respectively. Two putative CLRs, Clec4c and Sclra, are both required for maximal sensing of zymosan and NF-κB activation. Altogether, we identify conserved PRRs and PRR signaling pathways in larval zebrafish that promote recognition of fungal PAMPs. These results inform modeling of human fungal infections in zebrafish and increase our knowledge of the evolution and conservation of PRR pathways in vertebrates.

Indexed as

C-type lectin receptorsfungal cell wallpattern recognition receptorsToll-like receptorszebrafishzymosan

Identifiers

PMID38979385
PMCPMC11230284

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.